10x Genomics, Inc. 10-K Filing

FAQ

Key Financial Figures

• $0.00001 — stered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market L
• $610.8 million — armaceutical companies. Our revenue was $610.8 million and $618.7 million for the years ended
• $618.7 million — ies. Our revenue was $610.8 million and $618.7 million for the years ended 2024 and 2023, resp
• $182.6 million — rease of 1%. We generated net losses of $182.6 million and $255.1 million for the years ended
• $255.1 million — erated net losses of $182.6 million and $255.1 million for the years ended 2024 and 2023, resp
• $75 billion — ket opportunity We believe much of the $75 billion annual global life sciences research to
• $21 billion — a total addressable market of more than $21 billion annually, assuming every lab or company
• $13 billion — iceable addressable market of more than $13 billion annually, assuming every lab or company

Filing Documents

• txg-20241231.htm (10-K) — 1959KB
• txg-20241231xex108.htm (EX-10.8) — 77KB
• txg-20241231xex1017.htm (EX-10.17) — 41KB
• a231_eyfy2410kconsent.htm (EX-23.1) — 3KB
• txg-20241231xex311.htm (EX-31.1) — 10KB
• txg-20241231xex312.htm (EX-31.2) — 10KB
• txg-20231231xex321.htm (EX-32.1) — 5KB
• txg-20241231xex322.htm (EX-32.2) — 5KB
• a10x_logoxverticalxfullcol.jpg (GRAPHIC) — 77KB
• a10x_logoxverticalxfullcola.jpg (GRAPHIC) — 77KB
• txg-20241231_g1.jpg (GRAPHIC) — 223KB
• txg-20241231_g2.jpg (GRAPHIC) — 1255KB
• txg-20241231_g3.jpg (GRAPHIC) — 195KB
• txg-20241231_g4.jpg (GRAPHIC) — 204KB
• txg-20241231_g5.jpg (GRAPHIC) — 336KB
• txg-20241231_g6.jpg (GRAPHIC) — 267KB
• txg-20241231_g7.jpg (GRAPHIC) — 101KB
• 0001770787-25-000013.txt ( ) — 16128KB
• txg-20241231.xsd (EX-101.SCH) — 54KB
• txg-20241231_cal.xml (EX-101.CAL) — 103KB
• txg-20241231_def.xml (EX-101.DEF) — 271KB
• txg-20241231_lab.xml (EX-101.LAB) — 765KB
• txg-20241231_pre.xml (EX-101.PRE) — 540KB
• txg-20241231_htm.xml (XML) — 1243KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 12 Item 1B. Unresolved Staff Comments 58

C

Item 1 C . Cybersecurity 58 Item 2.

Properties

Properties 59 Item 3.

Legal Proceedings

Legal Proceedings 59 Item 4. Mine Safety Disclosures 59 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 60 Item 6. [Reserved] 61 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 62 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 74 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 76 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 109 Item 9A.

Controls and Procedures

Controls and Procedures 109 Item 9B. Other Information 110 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 111 PART III Item 10. Directors, Executive Officers and Corporate Governance 112 Item 11.

Executive Compensation

Executive Compensation 112 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 112 Item 13. Certain Relationships and Related Transactions, and Director Independence 112 Item 14. Principal Accounting Fees and Services 112 PART IV Item 15. Exhibits, Financial Statement Schedules 113 Item 16. Form 10-K Summary 116

Signatures

Signatures 117 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this "Annual Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended , and Section 21E of the Securities Exchange Act of 1934, as amended , which are subject to those sections' "safe harbor." All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding our plans, objectives, goals, beliefs, business strategies, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, gross margin trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, performance and benefits of our products and services, business trends and other information. These statements are based on management's expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.'s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Genomics, Inc. disclaims any obligation to update any published forw

Business

Item 1. Business. Overview Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience. Since launching our first product in mid-2015 through December 31, 2024, we have sold 7,039 instruments to researchers around the world, including academic and translational researchers and biopharmaceutical companies. Our revenue was $610.8 million and $618.7 million for the years ended 2024 and 2023, respectively, representing a year-over-year decrease of 1%. We generated net losses of $182.6 million and $255.1 million for the years ended 2024 and 2023, respectively. In the years ended December 31, 2024 and 2023, we sold 1,073 and 1,336 instruments and 357,100 and 347,000 consumable reactions, respectively. Our portfolios Resolution and Scale are the imperatives that underlie our products and technology. First, our solutions are designed to enable understanding biology at the right level of biological resolution, such as at the level of the single cell or at high spatial resolution of tissues and organs. Second, we believe that high resolution tools only become truly powerful when they are built into technologies with tremendous scale. Our products enable measuring up to millions o

View Full Filing

View this 10-K filing on SEC EDGAR